Krystal Biotech (KRYS) Share-based Compensation (2016 - 2026)

Krystal Biotech has reported Share-based Compensation for 11 years, with the latest figure at $14.2 million in Q2 2026.

• Share-based Compensation for Q2 2026 came in at $14.2 million, changed 0.26% year-over-year; the trailing twelve-month figure through Jun 2026 was $54.7 million (up 0.76% YoY), and the FY2025 annual result was $54.5 million, up 10.97% from the prior year.
• Share-based Compensation climbed to $14.2 million in Q2 2026, from $13.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $14.2 million in Q2 2026 and troughed at $6.4 million in Q1 2022.
• A 5-year average of $11.4 million and a median of $12.2 million in 2023 frame the typical range for Share-based Compensation.
• The widest annual swing landed in 2022, when Share-based Compensation surged 177.99%; it then declined 10.9% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $9.6 million in 2022, then increased by 3.15% to $9.9 million in 2023, then soared by 35.55% to $13.4 million in 2024, then increased by 3.05% to $13.8 million in 2025, then rose by 2.85% to $14.2 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $14.2 million in Q2 2026, $13.6 million in Q1 2026, and $13.8 million in Q4 2025.